Developer docs
API playgroundTry for free, no card

Search company profiles

AITRICS

Full company profile

uuid0000fb8

Namestring
AITRICS
Legal namestring
에이아이트릭스
Websiteurl
aitrics.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

AITRICS (에이아이트릭스) is a Seoul-based medical AI company founded in 2016 that develops clinical decision support software for hospitals, with its flagship product AITRICS-VC (VitalCare) — an FDA 510(k)-cleared, Korean MFDS-approved, and Malaysia Class C-approved software that ingests structured EHR data including vital signs, blood tests, and 19 EMR data types to predict patient deterioration, sepsis, ICU transfer, cardiac arrest, and mortality 4–6 hours in advance. The technology stack consists of proprietary deep learning models trained on multi-institutional clinical datasets spanning 5–7 years, paired with the MAES (Multimodal AI Explanation System) framework that uses attention layers to deliver feature and time-importance explainability for clinicians, and the proprietary MOCA medical LLM that powers the broader V.Doc/V.Doc Pro product family.

The company sells through direct enterprise sales to hospital systems, generating revenue via multi-year subscription or per-bed licensing arrangements negotiated per hospital based on size, integration complexity, and deployment scope. Distribution is entirely direct (no channel partners identified) with dedicated Solution Engineers handling EHR integration, and demand generation is anchored on conference presence (HIMSS, KIMES, ERS, EUSEM, MEDICA), peer-reviewed publications, and tier-1 academic hospital validation partnerships. Operating geographies span Korea (HQ in Seoul's Yeoksam-dong, Gangnam-gu), the US (Virginia branch opened August 2024 alongside FDA clearance), Malaysia (Class C approval), and Vietnam (Department of Health MOU in Hung Yen Province, 2026), with additional market signals in Hong Kong, Japan, the UAE, and Denmark.

Target customers are acute-care hospitals and their Rapid Response Teams seeking to reduce sepsis mortality and missed deterioration events, served alongside medical-affairs research partnerships with academic medical centers including Seoul Asan Hospital, Yonsei Severance Hospital, Chung-Ang University Hospital, and Hallym University Chuncheon Sacred Heart Hospital. Financially, AITRICS has raised approximately $54M cumulatively across 2020, 2021, 2024 Series B (~27.1B KRW / $20.3M) and November 2025 Series C (~35B KRW / $23.8M, led by SV Investment Corp), and has scaled to 180+ employees with a recent office relocation to a larger Yeoksam station facility. Leadership comprises co-founder/CEO Kim Kwang-joon (김광준), co-founder/CRO Yang Eun-ho (양은호), co-founder Professor Yoo Jin-gyu (유진규), alongside a CFO, COO, CSO, CMO and CBO.

Short descriptiontext

AITRICS is a Seoul-based medical AI company that develops FDA-cleared clinical decision support software (VitalCare) using proprietary deep learning and a proprietary medical LLM (MOCA) to predict patient deterioration and sepsis in hospital settings, sold through direct enterprise sales to acute-care hospitals in Korea, the US, Malaysia and Vietnam.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical decision support, sepsis prediction software, patient deterioration monitoring, EHR integrated AI, medical device software
Industry2 codes
PRIMARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SIC code2 codes
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
Product category
Clinical Decision Support Software
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Software Licensing
TypeSubscription Recurring
Description

AITRICS-VC is sold as a medical device software to hospitals. The company receives regulatory approval (Korean MFDS, US FDA, Malaysia MDA) and then licenses the software to healthcare institutions for integration with their EHR systems. Pricing is likely subscription or per-bed license model based on deployment scale.

hitnews.co.kr
2FDA-Cleared Software Distribution
TypeOne Time License
Description

Following FDA 510(k) clearance for AITRICS-VC, the company can commercialize the product in the US market. Revenue generated through direct hospital contracts and potential distributor partnerships.

koreabiomed.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise hospital deployment - Pricing based on hospital size and deployment scope
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing negotiated per hospital contract. Factors include number of beds, integration complexity, and term length.

koreabiomed.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1AITRICS-VC (VitalCare)
Description

AI-based medical device software for patient deterioration and sepsis prediction in hospital environments, providing clinical decision support integrated with hospital EHR systems.

hitnews.co.kr
+3 more records
Core offering1 text field

AITRICS develops and sells FDA-cleared, Korea MFDS-approved, and Malaysia Class C-approved AI clinical decision support software for hospitals. Its flagship product, AITRICS-VC (VitalCare), ingests structured EHR time-series data (vital signs, labs, 19 types of EMR records) to predict patient deterioration, sepsis, ICU mortality, cardiac arrest, and unexpected ICU transfer hours in advance. The company also markets V.Doc, an AI symptom checker, and V.Doc Pro, a generative AI medical co-pilot for clinicians.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Sepsis mortality reduced to approximately 10% with early prediction (within 1-3 hours of treatment initiation)
+2 more records
Product overview1 text field

AITRICS offers a unified medical AI platform anchored by VitalCare (AITRICS-VC), an FDA-cleared clinical decision support system that predicts patient deterioration, sepsis, and mortality. The product portfolio includes V.Doc (consumer-facing AI symptom checker), V.Doc Pro (medical co-pilot for healthcare professionals), and MOCA (proprietary medical LLM), all powered by the company's core AI technology for clinical decision support.

Product and service2 records
1AITRICS-VC (VitalCare)
CategoryClinical Decision Support / AI Medical Device Software
Description

Clinical decision support software that integrates with hospital EHR systems to predict patient deterioration, sepsis, mortality, cardiac arrest, and unexpected ICU transfer using deep learning models on vital signs, lab results, and 19 types of EMR data, with prediction horizons of 2-6 hours. Cleared by the US FDA (510(k)), Korea MFDS, and Malaysia Medical Device Authority (Class C). Targeted at acute care hospitals for use in general wards and ICUs.

2V.Doc
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Department of Health of Hung Yen Province, Vietnam
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-08
Description

MOU signed to explore AI adoption in healthcare, covering staff training, expert exchanges, and feasibility assessment in Vietnam's regulatory framework.

healthcareitnews.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Collaboration with Mayo Clinic Platform for product development and validation. Series C funding announcement specifically mentions Mayo Clinic Platform collaboration for AI copilot development and clinical validation.

3Seoul Asan Hospital Research Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-12
Description

MOU for joint research under the 'Research Hospital Cultivation Project' funded by Ministry of Health and Welfare. Focus on acute deterioration and severe patient diagnosis technology development and healthcare service innovation.

blog.aitrics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-12
Description

MOU for joint research on medical AI solutions, clinical studies, academic publications, national project collaboration, and new medical technology registration support.

5EunSung Medical Foundation (은성의료재단)
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-07-26
Description

Supply agreement for AITRICS-VC at Good Hospitals in Busan-Ulsan-Gyeongnam-Gyeongbuk region. Started with 3 hospitals (Good Culture, Good Samseon, Good Gang-an) with expansion plans to 11 facilities.

blog.aitrics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Prenosis developed the FDA-authorized Sepsis ImmunoScore, an AI diagnostics tool for early sepsis detection using EHR and biomarker data. Direct peer in AI-driven sepsis risk prediction targeting hospital systems, with similar FDA-cleared clinical decision support positioning.

2Dascena
TypeDirect peer
Description

Dascena (Informerati) built machine-learning models for sepsis and deterioration prediction using EHR data. Direct peer in AI-driven inpatient deterioration prediction targeting hospital systems, with overlapping product functionality to AITRICS-VC.

TypeDirect peer
Description

Etiometry provides FDA-cleared clinical decision support software for ICU patient monitoring and risk prediction. Direct peer in AI-based clinical decision support for acute/critical care settings with similar EHR-integrated deployment model.

4CLEW Medical
TypeDirect peer
Description

CLEW Medical offers AI-powered ICU analytics and early warning scores for clinical decision support. Direct peer in AI-driven patient deterioration prediction with similar enterprise hospital sales motion and FDA-cleared positioning.

TypeDirect peer
Description

Cytovale developed IntelliSep, an FDA-cleared AI-enabled cellular biomarker diagnostic for sepsis. Direct peer in AI-driven sepsis diagnostics for hospital settings, addressing the same use case (early sepsis detection) from a different modality.

TypeEmerging player
Description

Inflammatix develops host-response diagnostic tests augmented with AI for acute infection and sepsis triage. Comparable in targeting AI-enabled sepsis diagnostics for hospital use, but with a more diagnostics-oriented (sample-based) approach than AITRICS's EHR-based prediction.

TypeDirect peer
Description

Medical Informatics Corp's Sickbay platform provides FDA-cleared patient monitoring and clinical decision support integrating waveforms and EHR data. Direct peer in FDA-cleared, EHR-integrated inpatient monitoring AI for hospitals.

TypeBroad incumbent
Description

Philips offers broad patient monitoring, tele-ICU, and clinical decision support capabilities within its connected care portfolio. Comparable as a broad incumbent with overlapping hospital patient deterioration and ICU monitoring functionality, but at much larger scale and broader product portfolio.

TypeBroad incumbent
Description

GE HealthCare's Edison platform embeds AI-driven clinical decision support and patient monitoring into its hospital imaging and monitoring devices. Comparable as a broad incumbent operating in adjacent AI-enabled hospital decision support, with substantially larger distribution and customer footprint.

TypeBroad incumbent
Description

Health Catalyst provides analytics and AI-driven decision support platforms for hospital systems, including care management and clinical improvement modules. Comparable as a broader healthcare data/AI platform for hospitals, though less specialized in real-time deterioration prediction than AITRICS.

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AITRICS

Clinical Decision Support Softwareaitrics.com

AITRICS is a Seoul-based medical AI company that develops FDA-cleared clinical decision support software (VitalCare) using proprietary deep learning and a proprietary medical LLM (MOCA) to predict patient deterioration and sepsis in hospital settings, sold through direct enterprise sales to acute-care hospitals in Korea, the US, Malaysia and Vietnam.

What AITRICS does

AITRICS (에이아이트릭스) is a Seoul-based medical AI company founded in 2016 that develops clinical decision support software for hospitals, with its flagship product AITRICS-VC (VitalCare) — an FDA 510(k)-cleared, Korean MFDS-approved, and Malaysia Class C-approved software that ingests structured EHR data including vital signs, blood tests, and 19 EMR data types to predict patient deterioration, sepsis, ICU transfer, cardiac arrest, and mortality 4–6 hours in advance. The technology stack consists of proprietary deep learning models trained on multi-institutional clinical datasets spanning 5–7 years, paired with the MAES (Multimodal AI Explanation System) framework that uses attention layers to deliver feature and time-importance explainability for clinicians, and the proprietary MOCA medical LLM that powers the broader V.Doc/V.Doc Pro product family.

The company sells through direct enterprise sales to hospital systems, generating revenue via multi-year subscription or per-bed licensing arrangements negotiated per hospital based on size, integration complexity, and deployment scope. Distribution is entirely direct (no channel partners identified) with dedicated Solution Engineers handling EHR integration, and demand generation is anchored on conference presence (HIMSS, KIMES, ERS, EUSEM, MEDICA), peer-reviewed publications, and tier-1 academic hospital validation partnerships. Operating geographies span Korea (HQ in Seoul's Yeoksam-dong, Gangnam-gu), the US (Virginia branch opened August 2024 alongside FDA clearance), Malaysia (Class C approval), and Vietnam (Department of Health MOU in Hung Yen Province, 2026), with additional market signals in Hong Kong, Japan, the UAE, and Denmark.

Target customers are acute-care hospitals and their Rapid Response Teams seeking to reduce sepsis mortality and missed deterioration events, served alongside medical-affairs research partnerships with academic medical centers including Seoul Asan Hospital, Yonsei Severance Hospital, Chung-Ang University Hospital, and Hallym University Chuncheon Sacred Heart Hospital. Financially, AITRICS has raised approximately $54M cumulatively across 2020, 2021, 2024 Series B (~27.1B KRW / $20.3M) and November 2025 Series C (~35B KRW / $23.8M, led by SV Investment Corp), and has scaled to 180+ employees with a recent office relocation to a larger Yeoksam station facility. Leadership comprises co-founder/CEO Kim Kwang-joon (김광준), co-founder/CRO Yang Eun-ho (양은호), co-founder Professor Yoo Jin-gyu (유진규), alongside a CFO, COO, CSO, CMO and CBO.

AITRICS firmographics

Firmographics
Name
AITRICS
Legal name
에이아이트릭스
Website
https://aitrics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
AITRICS is a Seoul-based medical AI company that develops FDA-cleared clinical decision support software (VitalCare) using proprietary deep learning and a proprietary medical LLM (MOCA) to predict patient deterioration and sepsis in hospital settings, sold through direct enterprise sales to acute-care hospitals in Korea, the US, Malaysia and Vietnam.
Ownership category
akta.pro rank

AITRICS industry classification

Industry
Product category
Clinical Decision Support Software
SIC
Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Clinical decision support
  • Sepsis prediction software
  • Patient deterioration monitoring
  • EHR integrated AI
  • Medical device software

Where AITRICS is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

AITRICS business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Software Licensing: AITRICS-VC is sold as a medical device software to hospitals. The company receives regulatory approval (Korean MFDS, US FDA, Malaysia MDA) and then licenses the software to healthcare institutions for integration with their EHR systems. Pricing is likely subscription or per-bed license model based on deployment scale.
  2. FDA-Cleared Software Distribution: Following FDA 510(k) clearance for AITRICS-VC, the company can commercialize the product in the US market. Revenue generated through direct hospital contracts and potential distributor partnerships.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise hospital deployment - Pricing based on hospital size and deployment scope

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

AITRICS product offering

Product offering

Core offering

AITRICS develops and sells FDA-cleared, Korea MFDS-approved, and Malaysia Class C-approved AI clinical decision support software for hospitals. Its flagship product, AITRICS-VC (VitalCare), ingests structured EHR time-series data (vital signs, labs, 19 types of EMR records) to predict patient deterioration, sepsis, ICU mortality, cardiac arrest, and unexpected ICU transfer hours in advance. The company also markets V.Doc, an AI symptom checker, and V.Doc Pro, a generative AI medical co-pilot for clinicians.

Product overview

AITRICS offers a unified medical AI platform anchored by VitalCare (AITRICS-VC), an FDA-cleared clinical decision support system that predicts patient deterioration, sepsis, and mortality. The product portfolio includes V.Doc (consumer-facing AI symptom checker), V.Doc Pro (medical co-pilot for healthcare professionals), and MOCA (proprietary medical LLM), all powered by the company's core AI technology for clinical decision support.

Differentiator

Problem solved

Functional benefit

Brands

  • AITRICS-VC (VitalCare): AI-based medical device software for patient deterioration and sepsis prediction in hospital environments, providing clinical decision support integrated with hospital EHR systems.
  • V.Doc
  • V.Doc Pro
  • MOCA

Products and services

  • AITRICS-VC (VitalCare) Clinical decision support software that integrates with hospital EHR systems to predict patient deterioration, sepsis, mortality, cardiac arrest, and unexpected ICU transfer using deep learning models on vital signs, lab results, and 19 types of EMR data, with prediction horizons of 2-6 hours. Cleared by the US FDA (510(k)), Korea MFDS, and Malaysia Medical Device Authority (Class C). Targeted at acute care hospitals for use in general wards and ICUs.
  • V.Doc

Quantifiable outcome

  • Sepsis mortality reduced to approximately 10% with early prediction (within 1-3 hours of treatment initiation)
  • +2 more outcomes

Companies that use AITRICS

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

AITRICS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

AITRICS partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Department of Health of Hung Yen Province, VietnamminorStrategic or Co-development Partner · 8 May 2026MOU signed to explore AI adoption in healthcare, covering staff training, expert exchanges, and feasibility assessment in Vietnam's regulatory framework.
  • Mayo Clinic PlatformcoreStrategic or Co-development Partner · 1 December 2025Collaboration with Mayo Clinic Platform for product development and validation. Series C funding announcement specifically mentions Mayo Clinic Platform collaboration for AI copilot development and clinical validation.
  • Seoul Asan Hospital Research CentercoreStrategic or Co-development Partner · 12 January 2024MOU for joint research under the 'Research Hospital Cultivation Project' funded by Ministry of Health and Welfare. Focus on acute deterioration and severe patient diagnosis technology development and healthcare service innovation.
  • Chung-Ang University HospitalcoreStrategic or Co-development Partner · 12 January 2024MOU for joint research on medical AI solutions, clinical studies, academic publications, national project collaboration, and new medical technology registration support.
  • EunSung Medical Foundation (은성의료재단)coreImplementation/ SI/ Consulting Partner · 26 July 2023Supply agreement for AITRICS-VC at Good Hospitals in Busan-Ulsan-Gyeongnam-Gyeongbuk region. Started with 3 hospitals (Good Culture, Good Samseon, Good Gang-an) with expansion plans to 11 facilities.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

AITRICS competitors and assessment

Company assessment

Direct peers

  • Prenosis: Prenosis developed the FDA-authorized Sepsis ImmunoScore, an AI diagnostics tool for early sepsis detection using EHR and biomarker data. Direct peer in AI-driven sepsis risk prediction targeting hospital systems, with similar FDA-cleared clinical decision support positioning.
  • Dascena: Dascena (Informerati) built machine-learning models for sepsis and deterioration prediction using EHR data. Direct peer in AI-driven inpatient deterioration prediction targeting hospital systems, with overlapping product functionality to AITRICS-VC.
  • Etiometry: Etiometry provides FDA-cleared clinical decision support software for ICU patient monitoring and risk prediction. Direct peer in AI-based clinical decision support for acute/critical care settings with similar EHR-integrated deployment model.
  • CLEW Medical: CLEW Medical offers AI-powered ICU analytics and early warning scores for clinical decision support. Direct peer in AI-driven patient deterioration prediction with similar enterprise hospital sales motion and FDA-cleared positioning.
  • Cytovale: Cytovale developed IntelliSep, an FDA-cleared AI-enabled cellular biomarker diagnostic for sepsis. Direct peer in AI-driven sepsis diagnostics for hospital settings, addressing the same use case (early sepsis detection) from a different modality.
  • Medical Informatics Corp (Sickbay): Medical Informatics Corp's Sickbay platform provides FDA-cleared patient monitoring and clinical decision support integrating waveforms and EHR data. Direct peer in FDA-cleared, EHR-integrated inpatient monitoring AI for hospitals.

Emerging players

  • Inflammatix: Inflammatix develops host-response diagnostic tests augmented with AI for acute infection and sepsis triage. Comparable in targeting AI-enabled sepsis diagnostics for hospital use, but with a more diagnostics-oriented (sample-based) approach than AITRICS's EHR-based prediction.

Broad incumbents

  • Philips (eICU/Patient Monitoring): Philips offers broad patient monitoring, tele-ICU, and clinical decision support capabilities within its connected care portfolio. Comparable as a broad incumbent with overlapping hospital patient deterioration and ICU monitoring functionality, but at much larger scale and broader product portfolio.
  • GE HealthCare (Edison): GE HealthCare's Edison platform embeds AI-driven clinical decision support and patient monitoring into its hospital imaging and monitoring devices. Comparable as a broad incumbent operating in adjacent AI-enabled hospital decision support, with substantially larger distribution and customer footprint.
  • Health Catalyst: Health Catalyst provides analytics and AI-driven decision support platforms for hospital systems, including care management and clinical improvement modules. Comparable as a broader healthcare data/AI platform for hospitals, though less specialized in real-time deterioration prediction than AITRICS.

Market position

Competitive moat5 records

Key risks6 records

Customer concentration

AITRICS social profiles

Digital presence

AITRICS compliance and trust

Trust signal

Compliance2 records

AITRICS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AITRICS leadership team

Management profile

Number of profiles

Profiles7 records

AITRICS funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AITRICS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AITRICS

What does AITRICS do?

AITRICS develops and sells FDA-cleared, Korea MFDS-approved, and Malaysia Class C-approved AI clinical decision support software for hospitals. Its flagship product, AITRICS-VC (VitalCare), ingests structured EHR time-series data (vital signs, labs, 19 types of EMR records) to predict patient deterioration, sepsis, ICU mortality, cardiac arrest, and unexpected ICU transfer hours in advance. The company also markets V.Doc, an AI symptom checker, and V.Doc Pro, a generative AI medical co-pilot for clinicians.

Is AITRICS a public or private company?

AITRICS is a private company. It is classified as venture growth investor backed and is currently operating.

When was AITRICS founded?

AITRICS was founded in 2016. It employs 101 to 250 people.

Where is AITRICS based?

AITRICS is headquartered in Seoul, South Korea, in the Asia region.

How does AITRICS make money?

Two revenue lines are on record. Medical Device Software Licensing is the primary driver. The others are FDA-Cleared Software Distribution.

Who are AITRICS's main competitors?

Direct peers on record are Prenosis, Dascena, Etiometry, CLEW Medical, Cytovale and Medical Informatics Corp (Sickbay). Inflammatix is listed as an emerging player. Broad incumbents are Philips (eICU/Patient Monitoring), GE HealthCare (Edison) and Health Catalyst.

Does AITRICS have an API?

No public API is recorded for AITRICS.

What industry is AITRICS in?

AITRICS's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLACAGAA, Diagnostic & Triage Decision Support, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NaverHow AITRICS is Transforming Hospital Workflows with AI: Discover the Future of Medical EfficiencyAITRICS partnered with Gangbuk Samsung Hospital to develop an AI platform using large language models to automate outpatient records, imaging summaries, and nursing handovers. The company was selected as a consortium member for the 2026 AI Transformation Support Project at Seoul AI Hub. Both parties aim to validate the platform's effectiveness in real-world settings.VenturesquareAn AI with only high accuracy was insufficient... AItrix published research on predicting acute kidney injury in an international academic journal.AI Tricks published research in npj Digital Medicine on a deep learning model predicting acute kidney injury risk. The study analyzed 157,323 hospitalized patients from three institutions and found that the model with highest single-point accuracy was not best in clinical settings. It proposed evaluating time-stable performance and alert burden to select suitable AI models.Prtimes医療AI企業AIトリックス、健康経営支援サービス「V.Doc」PoC参加企業の募集を受付開始Aitrix Co., Ltd. began recruiting companies for a proof-of-concept of its health management service V.Doc, which uses AI to organize symptoms and connect employees to consultations. The service, developed by physicians, aims to support daily self-checks and corporate health management, with gradual introduction from PoC to full-scale rollout.VenturesquareAItrix partners with a top hospital in Japan... embarking on a medical AI demonstration in Yokohama.AI Tricks signed an MOU with Yokohama City University Hospital to jointly research AI medical devices, using ICU and internal medicine clinical data. The collaboration aims to develop patient monitoring and deterioration prediction systems, with plans to expand cooperation across Yokohama medical institutions.MobiHealthNewsMalaysia OKs Korean AI for sepsis prediction and more AI briefsMultiple AI healthcare developments across the Asia-Pacific and Latin American regions were announced this week, including AITRICS receiving Class C medical device approval from Malaysia's Medical Device Authority for its AI sepsis prediction software VitalCare. Taiwanese company Acer Medical partnered with Upsynergy Taiwan and Thai eye clinic New Eye to deploy an integrated ophthalmology AI and telemedicine ecosystem across five hospitals in Phuket Province. Separately, The Chinese University of Hong Kong signed a memorandum of understanding with Hangzhou Diagens Biotechnology to develop medical AI imaging for maternal and child healthcare in China's Greater Bay Area.VentureRadarNew Funding Rounds in "ai predictive analytics"Multiple companies are securing new financing rounds to develop and expand AI and predictive analytics solutions across various sectors, including healthcare, industrial operations, and business decision-making. Notable funding includes Hilbert raising $28M, Qventus securing $105M, and AITRICS receiving $24M in Series C funding.Venturesquare에이아이트릭스, KIMES 2026서 AI 기반 의료 솔루션 전시AITRICS, a medical AI company, announced its participation in KIMES 2026 (November 19–22) at COEX in Seoul, marking its 10th anniversary with the slogan 'AI That Understands You — Reshaping the Flow of Care.' The company will exhibit its clinical AI product lineup including V.Doc (AI symptom checker for general users), V.Doc Pro (medical co-pilot for healthcare professionals), AITRICS-VC (patient deterioration prediction), and its proprietary medical LLM MOCA. The exhibition aims to demonstrate how AI can be practically utilized throughout the entire medical process while strengthening the company's position as a leading medical AI provider.MobiHealthNewsAITRICS bags $24M Series C funding to boost copilot AI developmentKorean AI company AITRICS secured $24 million in Series C funding led by existing investors to enhance its flagship product VitalCare and develop a new clinician copilot. The company plans to expand into Vietnam and Hong Kong while leveraging a collaboration with Mayo Clinic for US market entry.VentureRadarNew Funding Rounds in AI diagnosticsThe article presents a curated list of recent venture capital funding rounds for various companies developing AI-driven diagnostics and healthcare technologies. Key transactions include AITRICS raising $24M, MultivisionDx securing €1M, and roclub obtaining $11.7 million to advance their respective clinical software and medical imaging solutions. The report highlights significant investment activity across the medtech and AI sectors without focusing on a single primary event.